## Amendments to the Claims:

Please amend the claims as shown in the following listing of claims, which will replace all prior versions and listings of claims in the application.

## 1.-20. (Canceled)

- 21. (New) A method of preventing, treating, and/or ameliorating one or more symptoms of a SARS-associated coronavirus infection comprising administering to a human infected with SARS-associated coronavirus a therapeutically effective amount of Glycyrrhizin or a derivative thereof.
- 22. (New) The method of claim 21, comprising administering to the human a compound of Formula (I):

$$H_3C$$
 $R_3$ 
 $CH_3$ 
 $C$ 

wherein  $R_1$ ,  $R_2$ , and  $R_3$  are independently: -OH; 5-, 6-, or 7-membered heterocycle; -Glycine-Leucine; -N(H) $R_4$ , wherein  $R_4$  is -5, 6-, or 7-membered heterocycle, or a pharmaceutically acceptable salt thereof.

23. (New) The method of claim 22, wherein  $R_1$ ,  $R_2$ , and  $R_3$  each is:

24. (New) The method of claim 21, comprising administering to the human a compound of Formula (I):

$$H_3C$$
 $R_3$ 
 $CH_3$ 
 $C$ 

wherein:

 $R_1$ ,  $R_2$ , and  $R_3$  are -N(H)R<sub>4</sub>, wherein R<sub>4</sub> is -5-, 6-, or 7-membered heterocycle (substituted or unsubstituted), with the proviso that R<sub>4</sub> is not thiazole, uracil or

25603785.1 4

one of R<sub>1</sub> and R<sub>2</sub> is:

and R3 and the other of  $R_1$  and  $R_2$  are independently -OH; -OCH3; -NH-NH2; -NHCH(COOH)CH<sub>2</sub>SCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>; 5-, 6-, or 7-membered heterocycle (substituted or unsubstituted); an amino acid; a peptide; -N(H)R<sub>4</sub>, wherein R<sub>4</sub> is -5-, 6-, or 7- membered heterocycle (substituted or unsubstituted);

one of  $R_1$ ,  $R_2$ , and  $R_3$  is an amino acid or a peptide and the other two of  $R_1$ ,  $R_2$ , and  $R_3$  are independently -OH; -OCH3; . -NH-NH<sub>2</sub>; -NHCH(COOH)CH<sub>2</sub>SCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>; 5-,6-, or 7-membered heterocycle (substituted or unsubstituted); -N(H)R<sub>4</sub>, wherein  $R_4$  is -5-, 6-, or 7-membered heterocycle (substituted or unsubstituted);

wherein R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are:

wherein R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are independently a 5-, 6-, or 7- membered heterocycle (substituted or unsubstituted), with the proviso that R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are not all proline;

or a pharmaceutically acceptable salt thereof.

- 25. (New) The method of claim 21, further defined as a method of inhibiting or reducing the multiplication of a SARS-associated coronavirus.
- 26. (New) The method of claim 21, further defined as a method of inhibiting or reducing the production of SARS-associated coronavirus particles.

25603785.1 5

- 27. (New) The method of claim 21, wherein Glycyrrhizin or the derivative thereof is purified.
- 28. (New) The method of claim 21, wherein the Glycyrrhizin derivative is 18β-Glycyrrhizinic acid.
- 29. (New) The method of claim 21, wherein the human infected with a SARS-associated coronavirus is an elderly human, a human infant, or an immunocompromised human.
- 30. (New) The method of claim 21 further comprising administering a therapeutically effective amount of a second antiviral agent other than Glycyrrhizin or a derivative thereof.
- 31. (New) The method of claim 30, wherein the second antiviral agent is Ribavirin.
- 32. (New) The method of claim 21, further defined as a method for preventing a SARS-associated coronavirus infection.
- 33. (New) The method of claim 32 wherein the subject has been exposed to a SARS-associated coronavirus infection.
- 34. (New) The method of claim 21, further defined as a method of treating a SARS-associated coronavirus infection.
- 35. (New) The method of claim 21, further defined as a method of ameliorating one or more symptoms of a SARS-associated coronavirus infection.
- 36. (New) A compound of Formula I:

$$H_3C_{II}$$
 $CH_3$ 
 $CH$ 

wherein:

 $R_1$ ,  $R_2$ , and  $R_3$  are -N(H)R<sub>4</sub>, wherein R<sub>4</sub> is -5-, 6-, or 7-membered heterocycle (substituted or unsubstituted), with the proviso that R<sub>4</sub> is not thiazole, uracil or

one of  $R_1$  and  $R_2$  is:

25603785.1

and R3 and the other of  $R_1$  and  $R_2$  are independently -OH; -OCH3; -NH-NH2; -NHCH(COOH)CH<sub>2</sub>SCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>; 5-, 6-, or 7-membered heterocycle (substituted or unsubstituted); an amino acid; a peptide; -N(H)R<sub>4</sub>, wherein R<sub>4</sub> is -5-, 6-, or 7- membered heterocycle (substituted or unsubstituted);

one of  $R_1$ ,  $R_2$ , and  $R_3$  is an amino acid or a peptide and the other two of  $R_1$ ,  $R_2$ , and  $R_3$  are independently -OH; -OCH3; . -NH-NH<sub>2</sub>; -NHCH(COOH)CH<sub>2</sub>SCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>; 5-,6-, or 7-membered heterocycle (substituted or unsubstituted); -N(H)R<sub>4</sub>, wherein  $R_4$  is -5-, 6-, or 7-membered heterocycle (substituted or unsubstituted);

wherein R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are:

wherein R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are independently a 5-, 6-, or 7- membered heterocycle (substituted or unsubstituted), with the proviso that R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are not all proline;

or a pharmaceutically acceptable salt thereof.

- 37. (New) A method comprising contacting a cell with an effective amount of Glycyrrhizin or a derivative thereof.
- 38. (New) The method of claim 37, further defined as a method of inhibiting or reducing the multiplication of a SARS-associated coronavirus.
- 39. (New) The method of claim 37, further defined as a method of inhibiting or reducing the production of SARS-associated coronavirus particles.

25603785.1